ELEV May 2024 5.000 call
| Previous close | 0.1000 |
| Open | 0.0500 |
| Bid | 0.0500 |
| Ask | 0.4000 |
| Strike | 5.00 |
| Expiry date | 2024-05-17 |
| Day's range | 0.0500 - 0.2000 |
| Contract range | N/A |
| Volume | |
| Open interest | 171 |
PR NewswireElevation Oncology to Present at the Citizens JMP Life Sciences Conference
Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced that Joseph J. Ferra, Chief Executive Officer of Elevation Oncology, will participate in a fireside chat at the Citizens JMP Life Sciences Conference on Tuesday, May 14, 2024, at 11:30 am ET.
- PR Newswire
Elevation Oncology Reports First Quarter 2024 Financial Results and Highlights Recent Business Achievements
Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced financial results for the quarter ended March 31, 2024, and highlighted recent business achievements.
- PR Newswire
Elevation Oncology Presents Preclinical Proof-of-Concept Data for HER3-ADC Program at AACR Annual Meeting 2024
Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced new preclinical data demonstrating proof-of-concept for its differentiated HER3-ADC program. The data will be presented in a poster session at the American Association for Cancer Research (AACR) Annual Meeting 2024, being held April 5-10 in San Diego, Ca
